Figures & data
Figure 1. Disease state transitions over 1 year.
Table 1. One year remission probabilities and response probabilities associated with conventional therapy, infliximab, adalimumab, and golimumab.
Table 2. Obtained costs of anti-TNF therapies, concomitant therapies, laboratory tests, and physician and specialist visits.
Figure 2. Cost per additional 1 year of remission (a) and cost per additional 1 year of response (b) simulation results depicted in relation to the anchor (conventional therapy); 8 week induction.
Figure 3. Cost-effectiveness acceptability curves for remission (a) and response (b); 8-week induction.
